中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
THE CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2015年
9期
728-730
,共3页
激素抵抗性前列腺癌%多西他赛%米托蒽醌%药品不良反应%生存时间
激素牴抗性前列腺癌%多西他賽%米託蒽醌%藥品不良反應%生存時間
격소저항성전렬선암%다서타새%미탁은곤%약품불량반응%생존시간
hormone resistance prostate cancer%docetaxel%mitoxantrone%adverse drug reaction%survival time
目的：评价多西他赛／米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌的临床疗效及安全性。方法入选80例激素抵抗性前列腺癌患者，并随机分为多西他赛联合泼尼松组38例（试验组）和米托蒽醌联合泼尼松组42例（对照组）。2组患者均口服泼尼松5.0 mg， bid，第1至21天，试验组联用多西他赛75 mg· m－2，静脉滴注，第1天；对照组联用米托蒽醌12 mg· m－2，静脉滴注，第1天。每21 d为1个周期，2组均治疗6个周期。比较2组患者的临床疗效、3年生存率及药品不良反应。结果治疗后，试验组的临床总有效率（76.3％）显著高于对照组的59.5％（ P＜0.05）。随访3年，试验组死亡10例，中位生存时间为826 d；对照组死亡11例，中位生存时间为534 d，试验组中位生存时间比对照组长（P＜0.05）；但2组药物不良反应发生率差异无统计学意义（P＞0.05）。结论多西他赛联合泼尼松治疗激素抵抗性前列腺癌的疗效显著，患者中位生存时间长。
目的：評價多西他賽／米託蒽醌聯閤潑尼鬆治療激素牴抗性前列腺癌的臨床療效及安全性。方法入選80例激素牴抗性前列腺癌患者，併隨機分為多西他賽聯閤潑尼鬆組38例（試驗組）和米託蒽醌聯閤潑尼鬆組42例（對照組）。2組患者均口服潑尼鬆5.0 mg， bid，第1至21天，試驗組聯用多西他賽75 mg· m－2，靜脈滴註，第1天；對照組聯用米託蒽醌12 mg· m－2，靜脈滴註，第1天。每21 d為1箇週期，2組均治療6箇週期。比較2組患者的臨床療效、3年生存率及藥品不良反應。結果治療後，試驗組的臨床總有效率（76.3％）顯著高于對照組的59.5％（ P＜0.05）。隨訪3年，試驗組死亡10例，中位生存時間為826 d；對照組死亡11例，中位生存時間為534 d，試驗組中位生存時間比對照組長（P＜0.05）；但2組藥物不良反應髮生率差異無統計學意義（P＞0.05）。結論多西他賽聯閤潑尼鬆治療激素牴抗性前列腺癌的療效顯著，患者中位生存時間長。
목적：평개다서타새／미탁은곤연합발니송치료격소저항성전렬선암적림상료효급안전성。방법입선80례격소저항성전렬선암환자，병수궤분위다서타새연합발니송조38례（시험조）화미탁은곤연합발니송조42례（대조조）。2조환자균구복발니송5.0 mg， bid，제1지21천，시험조련용다서타새75 mg· m－2，정맥적주，제1천；대조조련용미탁은곤12 mg· m－2，정맥적주，제1천。매21 d위1개주기，2조균치료6개주기。비교2조환자적림상료효、3년생존솔급약품불량반응。결과치료후，시험조적림상총유효솔（76.3％）현저고우대조조적59.5％（ P＜0.05）。수방3년，시험조사망10례，중위생존시간위826 d；대조조사망11례，중위생존시간위534 d，시험조중위생존시간비대조조장（P＜0.05）；단2조약물불량반응발생솔차이무통계학의의（P＞0.05）。결론다서타새연합발니송치료격소저항성전렬선암적료효현저，환자중위생존시간장。
Objective To evaluate the efficacy and safety of docetaxel or mitoxantrone combined with prednisone in the treatment of hormone resistance prostate cancer.Methods A total of 80 cases of hormone resistance prostate cancer were included in this study and were rando-mized divided into treatment group ( n=38 ) , treated with docetaxel 75 mg· m-2 on the first day combined with prednisone 5.0 mg bid from day 1 to day 21 and control group ( n=42 ) , treated with mitoxantrone 12 mg· m-2 combined with prednisone 5.0 mg bid from day 1 to day 21.With 21 days as a treatment cycle, the treatment lasted for 6 cycles.The data of clinical efficacy, 3-year survival rate and adverse drug reactions were evaluated between the two groups.Results The total efficacy were 76.3% ( 29/38 ) in treatment group and 59.5% ( 25/42 ) in control group with statistical difference (P<0.05).After 3 years follow-up, 10 cases died in treatment group and the median survival time was 826 days, and 11 cases died in control group and the median survival time was 534 days.The median survival date was statistically different between the two groups ( P <0.05 ).And the adverse drug reactions between two groups were not statistically different ( P >0.05 ) .Conclusion Compared with mitoxantrone, docetaxel combined with prednisone in the treatment of hormone resistance prostate cancer has achieved better clinical efficacy and longer median survival time.
